- Home
- WCN vs ARGX Comparison
WCN vs ARGX Comparison
Compare WCN & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCN
- ARGX
- Stock Information
- Founded
- WCN 1997
- ARGX 2008
- Country
- WCN Canada
- ARGX Netherlands
- Employees
- WCN N/A
- ARGX N/A
- Industry
- WCN Power Generation
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WCN Utilities
- ARGX Health Care
- Exchange
- WCN Nasdaq
- ARGX Nasdaq
- Market Cap
- WCN 45.9B
- ARGX 37.3B
- IPO Year
- WCN 1998
- ARGX 2017
- Fundamental
- Price
- WCN $174.31
- ARGX $623.82
- Analyst Decision
- WCN Buy
- ARGX Strong Buy
- Analyst Count
- WCN 19
- ARGX 20
- Target Price
- WCN $192.84
- ARGX $634.50
- AVG Volume (30 Days)
- WCN 1.1M
- ARGX 290.3K
- Earning Date
- WCN 02-11-2025
- ARGX 10-31-2024
- Dividend Yield
- WCN 0.72%
- ARGX N/A
- EPS Growth
- WCN 13.42
- ARGX N/A
- EPS
- WCN 3.64
- ARGX N/A
- Revenue
- WCN $8,694,917,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- WCN $12.12
- ARGX $61.99
- Revenue Next Year
- WCN $7.58
- ARGX $42.48
- P/E Ratio
- WCN $47.87
- ARGX N/A
- Revenue Growth
- WCN 10.68
- ARGX 85.56
- 52 Week Low
- WCN $145.35
- ARGX $349.86
- 52 Week High
- WCN $194.83
- ARGX $644.97
- Technical
- Relative Strength Index (RSI)
- WCN 25.19
- ARGX 58.04
- Support Level
- WCN $189.69
- ARGX $613.95
- Resistance Level
- WCN $187.20
- ARGX $644.97
- Average True Range (ATR)
- WCN 2.55
- ARGX 14.33
- MACD
- WCN -1.91
- ARGX -0.42
- Stochastic Oscillator
- WCN 5.79
- ARGX 50.28
About WCN Waste Connections Inc.
Waste Connections is the third-largest integrated provider of traditional solid waste and recycling services in the North America, operating 103 active landfills (9 are exploration and production waste landfills and 16 are nonmunicipal waste landfills), 157 transfer stations, and 81 recycling operations. The firm serves residential, commercial, industrial, and energy end markets. Waste Connections entered the Canadian market with its 2016 merger with Progressive Waste. In 2023, 12% of consolidated revenue was generated from the firm's Canadian segment.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.